NCT02839941

Iguratimod in Kidney Transplant Recipients

An Open-label Study to Evaluate the Effect of Iguratimod Concomitant With Conventional Immunosuppressive Drugs on Preventing Antibody-induced Rejection in Human Leukocyte Antigen(HLA) Highly Mismatched Kidney Transplant Recipients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to evaluate the effect of iguratimod concomitant with conventional immunosuppressive drugs on preventing antibody-induced rejection in HLA Highly mismatched Kidney Transplant recipients.

Conditions

• Kidney Transplantation

Interventions

Type	Name	Description
DRUG	Iguratimod	Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
DRUG	Mycophenolate mofetil	All subjects will receive mycophenolate mofetil for consecutive 52 weeks
DRUG	Tacrolimus	All subjects will receive tacrolimus for consecutive 52 weeks
DRUG	Glucocorticoids	All subjects will receive glucocorticoids for consecutive 52 weeks

Timeline

• Start date: 2016-08-01
• Primary completion: 2019-07-01
• Completion: 2019-07-01
• First posted: 2016-07-21
• Last updated: 2018-08-29

Locations

1 site across 1 country: China